Track REPL and 10,000+ stocks
Create a free account to build watchlists, compare peers, and value any stock.
- Build and track watchlists
- Compare against peers
- Earnings & price alerts
No credit card required
Replimune Group Inc
500 Unicorn Park Drive, Woburn, MA, United States, 01801
IPO
2018
Employees
465
Industry
Biotechnology
Sector
Healthcare
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer in the United States and the United Kingdom. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors. The company is also developing RP2 that expresses an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4. The company was founded in 2015 and is headquartered in Woburn, Massachusetts.
Insider Transactions
Quarterly buy vs. sell activity
Sell (left)Buy (right)
Q2 20261-1
0
Q4 20254-4
0
Q3 20251-1
0
Q2 20256-6
0
4-quarter cumulative
12 sells0 buys
Analyst Ratings
5 analysts covering
Buy100%recommend buy
Buy
5
Hold
0
Sell
0